Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.

Keyphrases

• Carboplatin 100%
• Irinotecan 100%
• Recurrent Non-small Cell Lung Cancer 100%
• 2-cycles 40%
• Non-small Cell Lung Cancer (NSCLC) 40%
• Metastatic Lung Cancer 40%
• Two-dose 20%
• Dose Reduction 20%
• 1-year Survival 20%
• Partial Response 20%
• Pathological Diagnosis 20%
• Stable Disease 20%
• Progressive Disease 20%
• Previous Chemotherapy 20%
• Hematologic 20%
• Diverticulitis 20%
• Neutropenic Fever 20%
• Pancreatitis 20%
• Febrile Neutropenia 20%
• Chemotherapy Cycles 20%
• CPT-11 20%
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 20%
• Cytological Diagnosis 20%
• Area under the Concentration-time Curve 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Carboplatin 100%
• Irinotecan 100%
• Lung Cancer 33%
• Febrile Neutropenia 33%
• Diseases 33%
• Survival Rate 16%
• Chemotherapy 16%
• Patient History of Chemotherapy 16%
• Diverticulitis 16%
• Pancreatitis 16%